The results here are provided for general informational purposes from the CMLviz Trade Machine Stock Option Backtester as a convenience to the readers. The materials are not a substitute for obtaining professional advice from a qualified person, firm or corporation.


There is a bullish momentum pattern in CRSP stock 14 calendar days before earnings. Further, we use moving averages as a safety valve to try to avoid opening a bullish position while a stock is in a technical break down, like the fourth quarter of 2018.

The Bullish Option Trade Before Earnings in CRISPR Therapeutics AG (NASDAQ:CRSP)

We will examine the outcome of getting long a monthly call option in CRISPR Therapeutics AG 14-days before earnings (using calendar days) and selling the call before the earnings announcement if and only if the stock price is above the 50-day simple moving average.

Here's the set-up in great clarity; again, note that the trade closes before earnings, so this trade does not make a bet on the earnings result.

And here is the technical analysis requirement -- note only one is "turned on," and that is the 50-day moving average requirement.:

If the stock price fails the technical requirement, it's fine, we just put a pin in it and check next quarter. Even better, we can set an intra day alert in Trade Machine that will email and/or text you when both requirements are met, just like this:


We can add another layer of risk management to the option trading back-test by instituting and 40% stop loss and a 40% limit gain. Here is that setting:

In English, at the close of each trading day we check to see if the long option is either up or down 40% relative to the open price. If it was, the trade was closed.


Here are the results over the last three-years in CRISPR Therapeutics AG:

The mechanics of the TradeMachine® stock option backtester are that it uses end of day prices for every back-test entry and exit (every trigger).

Notice that while this is a 3-year back-test and we would expect four times that many earnings triggers (4 earnings per year), the technical requirement using the 50-day moving average has avoided 6 pre-earnings attempts. In other words -- it's working.

We see a 482.7% return, testing this over the last 6 earnings dates in CRISPR Therapeutics AG. That's a total of just 84 days (14-days for each earnings date, over 6 earnings dates).

This is not a magic bullet, rather it's a bullish strategy. In the short-term it hasn't seen any losses, but more importantly, whether or not it loses on any given earnings run-up, the 482.7%  return in less than two-full months of trading is predicated on an idea of consistent momentum.

Setting Expectations

While this strategy had an overall return of 482.7%, the trade details keep us in bounds with expectations:

      The average percent return per trade was 75.41%.

Checking the Moving Average

You can check to see if the 50-day MA for CRSP is above or below the current stock price by using the Pivot Points tab on www.CMLviz.com.

Back-testing More Time Periods in CRISPR Therapeutics AG

Now we can look at just the last year as well:

We're now looking at 138.2% returns, on 2 winning trades and 0 losing trades.

      The average percent return over the last year per trade was 72.39%.


There's a better way to find winning option trades -- try pattern recognition.

Risk Disclosure

Past performance is not an indication of future results.

Trading futures and options involves the risk of loss. Please consider carefully whether futures or options are appropriate to your financial situation. Only risk capital should be used when trading futures or options. Investors could lose more than their initial investment.

Past results are not necessarily indicative of future results. The risk of loss in trading can be substantial, carefully consider the inherent risks of such an investment in light of your financial condition.

Please note that the executions and other statistics in this article are hypothetical, and do not reflect the impact, if any, of certain market factors such as liquidity and slippage.

You should read the Characteristics and Risks of Standardized Options.

Source link